Showing posts with label skin. Show all posts
Showing posts with label skin. Show all posts
Sunday, January 22, 2012
abstract: Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
"Due to the small number of randomized controlled trials conducted in the field of EGFR inhibitor-induced skin toxicity so far, it is not possible yet to generate evidence based guidelines on its management. Here, we review and discuss ($$$ requires subscription) available trials and case studies reporting on the management of EGFR inhibitor-induced skin toxicity."
Wednesday, March 30, 2011
Lynch Syndrome Hereditary Cancers Public Awareness Day | Fight Colorectal Cancer
Increased Risk of Cancer
If a parent carries a Lynch mutation there is a 50-50 chance that their child will inherit Lynch syndrome with- 60 to 80 percent increased lifetime risk of colorectal cancer.
- 40 to 70 percent increased risk of endometrial cancer (cancer of the uterus lining).
- 13 percent increased risk for stomach cancer
- 12 percent increased risk of ovarian cancer.
- smaller, but significant risk of small intestine, urinary tract, heptobiliary (liver, gall bladder and bile ducts), skin, and brain cancers.
- Some families may also have increased risk for breast cancer.
Lynch Syndrome is also noted for multiple primary cancers (different cancers in one person)
add your opinions
brain
,
breast
,
endometrial
,
heptibiliary
,
liver
,
Lynch Syndrome
,
ovarian
,
risk
,
skin
,
small intestine
,
stomach
,
urinary tract injury
,
uterus
Thursday, May 06, 2010
Scleroderma-like cutaneous lesions induced by paclitaxel and carboplatin for ovarian carcinoma, not a single course of carboplatin, but re-induced and worsened by previously administrated paclitaxel (Taxol)
"ABSTRACT
Scleroderma-like cutaneous lesion as an adverse event from paclitaxel and carboplatin has been reported. No report shows the occurrence of scleroderma-like cutaneous lesions from a single course of carboplatin. The patient is a 67-year-old female, administered paclitaxel and carboplatin as neoadjuvant chemotherapy. Following four courses, scleroderma-like cutaneous lesions were demonstrated. Skin biopsy corresponded to histopathological findings of scleroderma. Immunological investigation shows only antinuclear antibodies are positive. The characteristic Raynaud's phenomenon of scleroderma and hemorrhagic spots on the cuticles were not found. Postoperatively, a single course of carboplatin treatment was given. Scleroderma-like cutaneous lesions re-induced and worsened. This is the first report detailing scleroderma-like cutaneous lesions induced by previously administrated paclitaxel that worsened by carboplatin."
add your opinions
Carboplating
,
cutaneous
,
lesion
,
neoadjuvant therapy
,
Paclitaxel
,
scleroderma
,
skin
,
Taxol
Thursday, December 24, 2009
open access: Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management
Subjects carrying a mutation in one of the MMR genes have a higher risk for developing colorectal cancer, but also for endometrial carcinoma and malignancies of the stomach, small bowel, ovaries, upper uroepithelial tract, biliary tract, skin and brain.(pancreas)
add your opinions
bilary tract
,
brain
,
cancer
,
colorectal
,
endometrial
,
hereditary
,
HNPCC
,
Lynch Syndrome
,
ovarian
,
pancreas
,
skin
,
small bowel
,
stomach
,
uroepithelial tract
Subscribe to:
Posts
(
Atom
)